Skip to content

Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation

Evaluating Effectiveness of Barrier Measures to Limit Nosocomial Transmission: Covid-19 Prevalence Survey Among Caregivers With Various Exposures

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04376944
Acronym
EMBELLIE
Enrollment
300
Registered
2020-05-06
Start date
2020-04-01
Completion date
2020-12-30
Last updated
2020-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caregivers, COVID-19

Keywords

barrier measures

Brief summary

Use lay language. The Covid-19 pandemic hit France in March 2020 and stage 3 of the epidemic justified the introduction of national and unprecedented containment measures from March 17, 2020. The Montpellier CHU experienced peak hospitalizations of Covid-19 infections in late March. The estimate of the proportion of infected people in Occitania, South of France, for the 11th of May 2020 is 3.1% (95% CI: 1.9-5.9) for the Occitania region, to which Montpellier belongs. In the context of the Covid-19 epidemic, notably due to the absence of pharmacological or vaccine prophylaxis, barrier measures were of crucial importance, especially for exposed caregivers. These measures include an adaptation of individual behavior, the creation of a so-called Covid hospital, the wearing of specific equipment in all departments, the use in the rooms of Covid-19 patients of a gown, an apron, gloves, and a FFP2 type mask in the event of contact and sampling, protocolized and standardized bio-cleaning measures, a reorganization of the premises and the definition of specific circuits. In view of the second wave of the epidemic, estimating the effectiveness of the barrier measures is of major importance. The investigators therefore propose an evaluation of the effectiveness of these measures, by comparing the serological prevalence of infection among caregivers working directly in COVID units compared to caregivers working in services excluding the management of Covid-19 patients. Systematic evaluation in COVID-19 units of Sarc-Co-V2 infection will also be assessed, with naso-pharyngeal swabs.

Interventions

OTHERSurvey

questionnaire on their symptoms and their exposures

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* exposed group: exposed caregivers and agents who worked in COVID units (medicine, resuscitation, screening) until their date of collection. An exposed agent or caregiver is defined by the entrance of rooms with a COVID-19 infection during their professional activity. * low or unexposed group: caregivers or agents who have worked in non-COVID units in a non-COVID hospital

Exclusion criteria

\- refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Proportion of caregivers and agents with a positive serodiagnosis1 dayProportion of caregivers and agents with a positive serodiagnosis in COVID units versus non-COVID units

Secondary

MeasureTime frameDescription
Proportion of caregivers and agents with a positive RT-PCR1 dayProportion of caregivers and agents with a positive RT-PCR in COVID units versus non-COVID units

Countries

France

Contacts

Primary ContactAlain MAKINSON, MCU-PH
a-makinson@chu-montpellier.fr0663075260
Backup ContactMarie Bistoquet, MD
m-bistoquet@chu-montpellier.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026